For example, in the PDO model of BRCA1-deficient ovarian cancer, the combination of GPX4 inhibitors and PARP inhibitors can significantly enhance the synergistic anti-tumor effect induced by ferroptosis, which not only validates the reliability of PDO in predicting drug sensitivity but also provides an experimental basis for screening individualized treatment options for patients with specific genetic backgrounds [135]. Here, GPX4 is linked to neoplasm.